At WeightCare, the first important decision happens before the medical review: its published enrollment process asks customers to pay for the first month, then complete a health questionnaire. That sequence makes the refund policy part of the treatment decision, not an administrative detail to read later. The company advertises physician consultations, medication if approved, ongoing messaging and digital support, but the financial consequences depend on the specific plan and how far enrollment or fulfillment has progressed.
This documentary review examines WeightCare’s public pages consulted October 19, 2026, with particular attention to commitments, renewals and responsibility when something changes. The documentation provides meaningful prices and cancellation rules, yet also contains conflicting descriptions of dose coverage, state availability and some renewal amounts. WeightCare is documented as a GLP-1 telehealth provider; that does not verify its professional credentials, establish individual eligibility or demonstrate the effectiveness of its compounded products.
At a glance
- Payment precedes medical intake
- WeightCare says customers pay for the first month before completing health-history questions and receiving physician review.Sources: [8]
- Semaglutide commitment
- A three-month program costs $747 payable at the start, advertised as $249 per month; its dose-coverage descriptions conflict.Sources: [11]
- Monthly options
- Advertised no-commitment monthly prices are $399 for semaglutide, $499 for tirzepatide and $299 for topical tirzepatide HypoSpray.
- Renewal sequence
- WeightCare promises notice seven days before a renewal charge and says the refill medical questionnaire follows renewal processing.Sources: [8]
- Cancellation is not a refund
- The formal policy says cancellation stops future charges, not paid shipments, and already-billed time is not prorated or automatically refunded.Sources: [10]
The first contractual boundary is the questionnaire
WeightCare describes a straightforward but financially consequential enrollment sequence: payment first, health-history and weight-goal questions second, then review by a physician described as board certified. Its FAQ says its U.S. physicians are licensed and trained in weight management; those credentials were not independently verified for this review. A consultation is not a guaranteed prescription, and the company explicitly conditions included medication on medical approval.
The refund policy makes questionnaire submission a dividing line. Customers can contact WeightCare for a full refund before submitting it, or if their assigned physician determines they are ineligible for a prescription. After submission, refunds are generally unavailable, although the company says it considers requests and works toward a fair resolution. That exception language is discretionary; it is not a general satisfaction guarantee.
Before paying, a prospective customer should identify the selected product, program duration and applicable refund terms, then retain the confirmation. Our guide to reading enrollment terms explains why those details matter before intake begins. The consulted documentation does not clearly identify the operating legal entity, contracting medical entity or complete standard-program eligibility criteria. It also does not establish uniform laboratory requirements or a minimum clinical enrollment age.
Monthly prices describe different commitments
WeightCare’s semaglutide page offers a $399 monthly, no-commitment option alongside a three-month program costing $747, payable at the start and advertised as $249 per month. However, one block says that package covers all prescribed doses, while another labels the same $747 offer a starter plan for new patients and starter doses only. Those descriptions cannot safely be treated as interchangeable; dose coverage needs written confirmation.
Longer-plan prices introduce additional questions. Semaglutide is displayed at $215 per month for six months and $139 per month for 12 months, without a clear collection schedule in those passages. Tirzepatide is $499 month to month, while its three-month starter option is advertised at $299 per month for first-time GLP-1 users. Its 12-month, any-dose offer is $216 per month and expressly asks customers to commit to a year.
Separate high-dose tirzepatide programs target customers already taking medication or starting at a higher dose: $1,350 for three months, advertised as $450 monthly, or $2,150 for six months, advertised as $358 monthly. These are not the starter offer. A monthly price versus commitment comparison is especially useful here: an advertised monthly equivalent does not establish monthly cancellation rights, shipment quantity or how much is collected initially.
| Offer | Advertised price | Contract point to confirm |
|---|---|---|
| Semaglutide monthly | $399 per month; no commitment | Exact renewal amount and included formulation |
| Semaglutide three-month program | $747 payable at start; $249 monthly equivalent | All prescribed doses versus new-patient starter-dose restriction |
| Tirzepatide three-month starter | $299 per month | First-time GLP-1 positioning; initial collection and subsequent charges |
| Tirzepatide 12-month, any-dose plan | $216 per month | Annual commitment; billing and early-exit terms |
| Topical compounded tirzepatide HypoSpray | $299 per month; no commitment | Product-specific renewal terms and state availability |
Renewal happens before the refill questionnaire
WeightCare promises a notification seven days before any upcoming renewal charge. Its stated sequence then places the refill medical questionnaire after renewal processing, allowing patients to report progress to their doctor. That distinction matters: the published process does not describe a fresh clinical questionnaire completed before each charge. Patients should ask what happens to a processed renewal if a subsequent review changes or ends the prescription.
Another problem is inconsistent renewal language. FAQ material reproduced across product pages advertises a $499 monthly renewal, including on pages whose headline monthly prices differ, such as semaglutide and the spray. It would be inappropriate to conclude that every product renews at $499. Equally, the lower headline price should not be assumed to control without a product-specific checkout confirmation stating the next charge and its date.
The seven-day notice is a notification promise, not a documented cancellation deadline. The reviewed passages do not establish a universal minimum notice period for stopping renewal. Customers should verify the account’s actual next billing date and obtain confirmation that cancellation took effect. A reminder email is useful, but the decisive records are the selected terms, the account status and the company’s acknowledgment—not a general “cancel anytime” slogan.
Cancellation stops future charges, not completed obligations
The FAQ directs cancellation requests to help@joinweightcare.com with CANCEL in the subject line and says a customer-service agent will confirm cancellation. The formal policy also says customers can cancel in their account. The consulted subscription-management material did not show the actual account screens or steps, so this review cannot verify the self-service experience. Keeping the request and confirmation is particularly important when a renewal is approaching.
The formal policy is clearer than the promotional language about financial consequences. Cancellation stops future charges but does not itself refund money or stop shipments already paid for. Customers retain their program through the paid period, and already-billed time is not prorated or refunded. Thus, ending renewal on a multimonth purchase is not necessarily the same as recovering the unused portion of that purchase.
If WeightCare approves a refund after a multimonth program has partially shipped, it deducts the medication received at the regular price of the matching package, using the dose and original purchase date. This is not a simple unused-month calculation. The company also says medication cannot be returned or refunded once it leaves the pharmacy. Our explanation of refund boundaries can help distinguish eligibility for review from a promised reimbursement.
Included care has several separate timelines
WeightCare advertises a program subscription, a same-day telehealth visit with a board-certified physician, prescription and medication if approved, and unlimited physician messaging. The tirzepatide page additionally describes monthly check-ins and secure messaging at any time. Its FAQ promises an update from the assigned physician within one business day. Same-day consultation, messaging access and response time are distinct service claims, not one promise of immediate care throughout enrollment.
Digital support includes a member coaching app advertising customized nutrition plans, exercise videos, podcast material, educational resources and tracking for sleep, body metrics, hydration, exercise and nutrition. The provider also describes its telehealth platform as HIPAA compliant, a claim not independently assessed here. These features document the advertised bundle, but do not establish how quickly an individual issue will be resolved or whether every plan has identical access.
The company says prescriptions are filled and shipped by an accredited U.S. pharmacy, without naming that pharmacy in the quoted passage. Arrival is advertised within five to seven business days after the prescription is written—not after payment—with ice packs, shipment confirmation and tracking. Patients are asked to refrigerate medication on arrival. Before enrollment, clarify the platform, clinician and pharmacy responsibilities, including who handles a delayed, damaged or temperature-compromised shipment.
State eligibility belongs to the exact product
The general FAQ lists three-month semaglutide and tirzepatide weight-loss programs as unavailable in Alaska, Hawaii, Louisiana and Mississippi. Yet the semaglutide plan comparison adds Alabama, conflicting with other availability language. The high-dose tirzepatide page adds California to the four-state exclusion list. These differences make a broad statement that WeightCare serves a particular state insufficient: the product, presentation and plan need to match.
HypoSpray has its own exclusions: Alaska, Alabama, Arkansas, California, Hawaii, Mississippi and Louisiana. Three-month semaglutide microdosing excludes Alaska, Arkansas, California, Hawaii, Kentucky, Louisiana, Mississippi, Montana and South Carolina. The general FAQ also advertises three-month semaglutide and tirzepatide microdosing plans for weight management at BMI 20 or above. That marketing threshold is not automatic medical approval or a complete eligibility standard.
Geographic confirmation should occur before payment, particularly where pages disagree. Ask the company to identify the exact plan available at the delivery address and whether the intended pharmacy can fulfill that prescription there. The consulted documentation does not establish Spanish-language care, interpretation or Spanish forms and app access. Anyone requiring those services should confirm them directly rather than treating a generally accessible website as evidence of language support.
Financing and support do not erase the underlying terms
WeightCare offers Affirm at checkout for its three- and six-month weight-loss programs and three-month microdosing programs. The stated requirements include U.S. residency, age 18 or older, a Social Security number and a phone that receives text messages. Financing is subject to eligibility checks, with advertised APR options from 0% to 36%. Approval for credit and approval for treatment are separate; the company says not everyone qualifies for either.
Financing should not be confused with a flexible month-to-month treatment contract. Before using it, customers need the purchase amount, repayment terms and the consequences of cancellation or an approved refund explained separately. WeightCare also says prescription weight-loss expenses may qualify for FSA or HSA use depending on the individual plan. That statement does not establish direct insurance billing, prior-authorization assistance or guaranteed coverage of the medication or consultation.
For refund requests, the policy lists info@joinweightcare.com and 844-228-1344. Approved refunds go to the original payment method and typically post within five to ten business days; that is not a guaranteed bank-arrival deadline. General support lists help@joinweightcare.com, 954-852-9344 and 844-228-1344. Published weekday hours conflict: the FAQ says 9 a.m.–6 p.m. EST, while Support Survey says 10 a.m.–6 p.m. EST.
A clear contract still needs a clearly identified medicine
WeightCare’s semaglutide and tirzepatide product pages explicitly disclose that their compounded products are not FDA approved. It separately markets HypoSpray as topical compounded tirzepatide delivered through the skin rather than injected. That delivery claim belongs to the provider; the consulted documentation does not establish clinical evidence verifying its absorption or benefits. General references to injectable tirzepatide do not identify the device or presentation each patient would receive.
FDA approval attaches to a specific product, not to WeightCare or a dispensing pharmacy. Compounded preparations do not undergo FDA premarket review for safety, effectiveness and quality, although nonapproval alone does not prove clinical inequivalence. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Injectable trial findings cannot simply be assigned to topical products, microdoses or this provider’s preparations.
Before accepting fulfillment, ask for the formulation, route, presentation, dispensing pharmacy and clear administration instructions. FDA has reported measurement and administration errors involving compounded GLP-1 medicines; a review should not substitute for prescriber or pharmacist instructions. For an injectable GLP-1 delivery that arrives warm or inadequately refrigerated, FDA explicitly advises not using the product and contacting the provider or dispensing pharmacy. The appropriate response is a documented resolution, not an assumption that ice packs guarantee acceptable conditions.
Questions & answers
Will WeightCare refund me if I am not approved?
Its policy says to contact the company for a full refund if the assigned physician determines you are not eligible for a prescription. It also allows a full-refund request before questionnaire submission. After submission, refunds are generally unavailable unless an applicable exception or discretionary resolution applies. Payment itself does not guarantee a prescription.
Does the $747 semaglutide package cover higher doses?
The public page gives conflicting answers. One description says the three-month, upfront-paid package covers all doses prescribed by the physician. Another identifies the $747 package as restricted to new patients and starter doses. Obtain written confirmation of coverage for the selected offer rather than assuming the broader statement overrides the restriction.
How do I cancel WeightCare?
The FAQ says to email help@joinweightcare.com with CANCEL in the subject line and receive agent confirmation. The formal policy also describes account cancellation. Cancellation stops future charges, but does not automatically refund the paid period or stop paid shipments. Verify the next renewal date and retain confirmation that the request was completed.
Is HypoSpray the same offering as injectable tirzepatide?
No. WeightCare markets HypoSpray as topical compounded tirzepatide delivered through the skin, with a $299 no-commitment monthly option and its own state exclusions. Injectable-product descriptions and research do not establish the topical product’s performance. Ask for the exact formulation and evidence relevant to that route before treating the offers as equivalent.
Does the five-to-seven-business-day estimate start when I pay?
No. WeightCare measures the advertised arrival window from when the prescription is written. Payment, questionnaire completion, medical review and prescribing precede that shipping clock. The company says it provides tracking and ships with ice packs. Its same-day consultation claim and one-business-day physician-update claim are separate from the medication arrival estimate.
Can I assume WeightCare accepts my insurance or HSA?
No. WeightCare says FSA or HSA eligibility depends on your specific plan and recommends checking before starting. That is not confirmation of direct insurance billing or medication coverage. Affirm is a separate financing option with eligibility checks and advertised APRs of 0%–36%; it should not be mistaken for insurance or guaranteed interest-free payments.
Our assessment
WeightCare documents a substantive telehealth bundle, several genuinely distinct payment options and unusually explicit cancellation-versus-refund boundaries. Its main contractual weakness is inconsistency: dose coverage, state exclusions and renewal language do not always align, while longer-plan collection schedules remain incompletely explained. The practical next step is a written, product-specific confirmation covering the initial charge, renewal amount, commitment, dose coverage, pharmacy and refund consequences. Customers seeking flexibility should distinguish the advertised monthly options from multimonth or annual commitments. Clearer terms would improve decision-making, but neither contract clarity nor an included prescription establishes clinical suitability or results.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- Wilding et al. (2021): STEP 1 semaglutide trial ↗
- Jastreboff et al. (2022): SURMOUNT-1 tirzepatide trial ↗
- WeightCare — products/tirzepatide spray ↗
- WeightCare — products/tirzepatide high dose program ↗
- WeightCare — pages/support survey ↗
- WeightCare — pages/how it works ↗
- WeightCare — pages/faq ↗
- WeightCare — blogs/tirzepatide/understanding tirzepatide how it works and what to expect%20 ↗
- WeightCare — policies/refund policy ↗
- WeightCare — products/semaglutide weight loss program ↗
- WeightCare — products/tirzepatide ↗